The combination of ledipasvir + sofosbuvir was highly effective in a small study of people with HCV genotype 6.
Researchers recruited 25 participants with the following average profile:
After 12 weeks of ledipasvir + sofosbuvir, 96% (24 of 25 participants) achieved an SVR12.
At this time further information about the trial is not available. However, note that the study was small and the results, although very promising, require confirmation in a larger clinical trial.
Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infections. In: Program and abstracts of The Liver Meeting, 7-11 November 2014. Abstract LB-11.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|